In 2022, the Danish pharmaceutical company Novo Nordisk reported that its long-acting insulin medication Levemir® had generated about 0.54 billion Danish kroner in Greater China. After two years of launching its another long-acting insulin product Tresiba® in China, the firm had recorded a significant sales growth of the medication in 2021.
Net sales of diabetes and obesity care medications of Novo Nordisk in Greater China in 2022, by key product
(in million DKK)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Novo Nordisk. (February 6, 2023). Net sales of diabetes and obesity care medications of Novo Nordisk in Greater China in 2022, by key product (in million DKK) [Graph]. In Statista. Retrieved December 30, 2024, from https://www.statista.com/statistics/1120873/greater-china-net-sales-of-novo-nordisk-top-diabetes-care-medicines/
Novo Nordisk. "Net sales of diabetes and obesity care medications of Novo Nordisk in Greater China in 2022, by key product (in million DKK)." Chart. February 6, 2023. Statista. Accessed December 30, 2024. https://www.statista.com/statistics/1120873/greater-china-net-sales-of-novo-nordisk-top-diabetes-care-medicines/
Novo Nordisk. (2023). Net sales of diabetes and obesity care medications of Novo Nordisk in Greater China in 2022, by key product (in million DKK). Statista. Statista Inc.. Accessed: December 30, 2024. https://www.statista.com/statistics/1120873/greater-china-net-sales-of-novo-nordisk-top-diabetes-care-medicines/
Novo Nordisk. "Net Sales of Diabetes and Obesity Care Medications of Novo Nordisk in Greater China in 2022, by Key Product (in Million Dkk)." Statista, Statista Inc., 6 Feb 2023, https://www.statista.com/statistics/1120873/greater-china-net-sales-of-novo-nordisk-top-diabetes-care-medicines/
Novo Nordisk, Net sales of diabetes and obesity care medications of Novo Nordisk in Greater China in 2022, by key product (in million DKK) Statista, https://www.statista.com/statistics/1120873/greater-china-net-sales-of-novo-nordisk-top-diabetes-care-medicines/ (last visited December 30, 2024)
Net sales of diabetes and obesity care medications of Novo Nordisk in Greater China in 2022, by key product (in million DKK) [Graph], Novo Nordisk, February 6, 2023. [Online]. Available: https://www.statista.com/statistics/1120873/greater-china-net-sales-of-novo-nordisk-top-diabetes-care-medicines/
